Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

New England Journal of Medicine (12/21/95) Vol. 333, No. 25, P. 1662
Eron, Joseph J.; Benoit, Sharon L.; Jemsek, Joseph; et al.

To determine the safety and activity of lamivudine plus zidovudine in the treatment of HIV-infection, as compared with either drug alone, Eron et. al. studied more than 360 patients with CD4 levels between 200 and 500 cells. During the double- blind, 24-week study, patients were randomly assigned to receive either lamivudine, zidovudine, or one of two dose levels of a combination lamivudine plus zidovudine. The researchers found that the low- and high-dose regimens of the combination therapy resulted in greater increases in CD4 cell counts and percentage of CD4 cells, as well as larger reductions in HIV-1 RNA plasma levels, versus zidovudine alone. The combination treatment was also more effective in reducing HIV-1 RNA levels and increasing CD4-cell percentages than lamivudine alone--benefits which were maintained through the 28-week extension phase of the study. The researchers concluded that such combination therapy was well-tolerated in the 52 weeks of study, and that it generates more immunologic and virologic improvement than either drug by itself.

951229
AD952309

Copyright © 1995 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.